Experts of the European medicines Agency EMA have recommended that an Ebola vaccine that is already used in the current Ebola outbreak in the Democratic Republic of the Congo, in the EU, to allow. For the approval the approval of the European Commission is still required, but it is considered likely.
Between 2014 and 2016, more than 11,000 people in West Africa in the largest Ebola outbreak have died. The development of a vaccine is considered a milestone in the fight against the disease, against which there is as yet no therapy. In 2014, the Paul-Ehrlich-Institute (PEI) has been involved in clinical studies on the efficacy and safety of the vaccine. "I am pleased that the PEI, with its diverse range of initiatives to promote clinical audit and development of the Ebola vaccine and so also to the establishment of the manufacture at the location Germany contribute konnte", Professor Klaus Cichutek, President of the PEI said.
The vaccine is a live attenuated vaccine that is genetically engineered and, so far, 16,000 people have been tested. Previous studies have shown that a single vaccination protects against the disease. For approval in Europe, a special accelerated procedure has been applied, in order to make it accessible.
Currently, about Doctors and nurses and people who had contact with Patients be vaccinated with the vaccine in the Democratic Republic of the Congo, people with a high risk of infection,. There are 3,000 people with the Ebola Virus, the mortality rate is currently about 67 percent is still very high. The world health organization (WHO) called the outbreak in July of this year, therefore, as an emergency of international importance.
An Overview of all the messages you get on aponet.de current.